
    
      Patients would be evaluated whether meet the criteria as clinical stage T1 ground-glass
      dominated invasive lung adenocarcinoma. Then, he/she would be randomly divided into the two
      arms. One is receiving systematically mediastinal lymph node dissection. The other is not
      receiving systematically mediastinal lymph node dissection. Finally, disease free survival
      would be recorded in the follow-up period.
    
  